Eli Lilly Files Six Lawsuits Over Black Market Sales of Retatrutide
Nashnova编辑部
Eli Lilly sued six entities — compounding pharmacies, med-spas and online sellers — for selling retatrutide, an experimental weight-loss drug still in Phase III trials and not approved for human use anywhere; the move signals an escalation in the three-way crackdown by the drugmaker, regulators and law enforcement.
Who did Lilly sue, and why?
The six defendants are Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co — a mix of compounding pharmacies, cosmetic clinics and online peptide vendors.
The core allegation: retatrutide is still in Phase III clinical trials, has no regulatory approval for human use, yet these entities sold it directly to consumers.
This means → buyers are not getting "an early version of a new drug." They are getting a completely unverified experimental substance with no safety guarantees.
What is retatrutide, and why is there a black market for it?
Retatrutide is Lilly's next-generation weight-loss candidate, currently in Phase III trials for obesity, type 2 diabetes and related conditions.
In plain terms = it has not even finished its final exam, but the weight-loss drug market is so hot that the black market could not wait.
Lilly's chief medical officer David Hyman put it bluntly: "What's being sold on the black market is not medicine — it's completely unverified, unapproved and high-risk."
What have regulators and law enforcement done so far?
Lilly has referred more than 200 individuals and entities to the FDA, the Department of Justice, state attorneys general and licensing boards.
In June, the FDA stated explicitly that selling retatrutide and other unapproved GLP-1 products to consumers is illegal and that the drug may not be legally compounded.
U.S. Customs data shows 690-plus seizures totaling over 31,000 units of illicit GLP-1 drugs in fiscal 2025; in July alone, seizures topped 1,400 shipments and nearly 90,000 vials — more than double the prior month.
This reflects a black market expanding far faster than enforcement can keep up.
Who else does Lilly want in the fight?
Lilly called on social-media platforms, e-commerce sites, payment processors, credit-card companies and logistics firms to crack down on unauthorized retatrutide sellers.
This means → Lilly sees lawsuits and regulation alone as insufficient; it wants the black market choked at three chokepoints: traffic, payments and shipping.
What comes next?
Whether the six lawsuits deter further black-market expansion depends on how fast courts move and how aggressively regulators coordinate enforcement.
Lilly's global patient-safety lead for cardiometabolic health, Max Denning, warned: "Every time someone uses these products, they are exposing themselves to enormous risk."
In plain terms = the lawsuits are just the opening move; the real battle is making the black market unable to sell, unable to collect payment and unable to ship.
Content is for reference only, not financial advice.